ProQR Therapeutics N.V. (PRQR)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.9900 |
| Open | 1.9400 |
| Bid | 2.1400 x 900 |
| Ask | 2.1500 x 1800 |
| Day's Range | 1.9400 - 2.2200 |
| 52 Week Range | 0.5300 - 3.8500 |
| Volume | |
| Avg. Volume | 1,281,972 |
| Market Cap | 172.14M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6500 |
| Earnings Date | May 03, 2023 - May 08, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.14 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for PRQR
Related Research
- ProQR Therapeutics N.V.QURE: Raising target price to $27.00UNIQURE NV has an Investment Rating of BUY; a target price of $27.000000; an Industry Subrating of Medium; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of Medium.RatingFair ValueEconomic Moat4 days agoArgus Research
- Motley Fool
Why Shares of ProQR Therapeutics Dropped on Wednesday
Shares of ProQR Therapeutics (NASDAQ: PRQR) were down 31% Wednesday morning after the company reported 2022 full-year earnings and updated the status of its pipeline. ProQR is a clinical-stage biopharmaceutical company that focuses on RNA-based therapies to treat rare genetic diseases, especially inherited eye diseases. ProQR released its fourth-quarter and full-year earnings before the market opened on Wednesday, along with an update regarding its pipeline.
- GlobeNewswire
ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event
Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1; initiation of clinical trials anticipated in late 2024/early 2025Axiomer activity demonstrated across multiple preclinical in vitro, organoid, and in vivo models; up to 50% editing observed in rodent and non-human primatesBeyond correction, broad applicability of Axiomer demonstrated in preclinical models with ability to modulate proteins by altering function
- GlobeNewswire
ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it has successfully defended against two oppositions that were filed against a key patent for its ADAR-mediated RNA editing platform Axiomer®. The oppositions were filed in February 2021 with the European Patent Office (EPO) by two separate strawmen against ProQR’s granted patent EP 3
